Laboratorios Ordesa
1
12M
1
0.01
1
- Stages of investment
- Areas of investment
Summary
In 1943 was created Laboratorios Ordesa, which is appeared as Corporate Investor.
Among the various public portfolio startups of the fund, we may underline Oryzon Genomics Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Therapeutics, Biotechnology.
The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2015. The top activity for fund was in 2008. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The typical case for the fund is to invest in rounds with 2 participants. Despite the Laboratorios Ordesa, startups are often financed by Najeti Capital, Grupo Ferrer Internacional. The meaningful sponsors for the fund in investment in the same round are Corsabe Capital. In the next rounds fund is usually obtained by Alzheimer's Drug Discovery Foundation.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.01
- Investments by industry
- Therapeutics (1)
- Genetics (1)
- Medical (1)
- Biotechnology (1)
- Investments by region
-
- Spain (1)
- Peak activity year
- 2008
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Oryzon Genomics | 12 Mar 2008 | Biotechnology, Genetics, Medical, Therapeutics | Early Stage Venture | 12M | Spain, Madrid, Community of Madrid |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.